Peptide · Fact sheet

Thymosin beta-4

Also known as Tβ4 · TB4 · full-length thymosin beta-4 · TB-500 (fragment marketed online)

Thymosin beta-4 is a naturally occurring peptide involved in cell movement and tissue processes. Experimental full-length products and the TB-500 fragment marketed online should not be treated as proven or interchangeable therapies.

Not FDA approvedMostly animal or lab research

What is Thymosin beta-4?

Thymosin beta-4 is present in many tissues and has roles involving actin, cell movement, inflammation, and repair signaling.

TB-500 commonly refers to a shorter fragment marketed online. Evidence about full-length thymosin beta-4 cannot automatically be applied to that fragment or to an unverified product.

Benefits & claims

It is discussed for injury recovery, wound healing, heart repair, eye conditions, and athletic performance.

Much of the enthusiasm comes from mechanistic or preclinical research rather than proven clinical outcomes.

What the evidence supports

  • Preclinical research suggests roles in cell migration, blood-vessel formation, and tissue repair.
  • Early studies do not establish a general injury-recovery or athletic-performance treatment.
Research areas
  • Tissue and wound repair
  • Corneal healing
  • Cardiac repair
  • Inflammation
  • Cell migration
  • Topical and systemic tissue-repair applications in research settings

Dosage & frequency

No established human regimen

Thymosin beta-4 eye-drop trials do not establish an injectable TB-500 regimen for injury recovery.

How to read these amounts

An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.

Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences

Formulations, interactions & practical context

Formulation differences

  • Full-length thymosin beta-4, TB-500 fragments, and RGN-259 eye drops are different products and evidence.

Interactions & precautions

  • Ophthalmic trial evidence does not establish drug interactions for systemic thymosin beta-4 or TB-500 fragments.

What is still unresolved

  • An effective systemic repair dose, frequency, and long-term safety profile remain unestablished.

Side effects & risks

  • FDA notes potential immune reactions, aggregation, peptide impurities, and a lack of identified human exposure data for the TB-500 fragment in drug products.
  • Systemic effects and long-term consequences are insufficiently understood.
  • Online products add identity, purity, sterility, and labeling uncertainty.

This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.

Clinical research

Mostly animal or lab research

There are early human studies in selected areas, but the broad recovery claims seen online are supported mainly by preclinical evidence.

Studies

Personal experiences

Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.

Explore 3 sourced accounts by reported effect.

Sleep: reported experiences

Negative account · personal report

Severe anxiety, sleeplessness and chest tightness

A different person reported these symptoms after exposure to products labeled BPC-157 and TB-500, including seeking hospital assessment.

Reported use in this account

Product
Products labeled BPC-157 and TB-500; full-length thymosin beta-4 identity not established
Amount
Not specified clearly
Frequency
Not specified clearly
Route
Subcutaneous injection
Duration
Three days before the reported severe reaction

Other exposures described: BPC-157; Propranolol given after symptoms

Combined exposure and unverified product identity prevent attribution to either substance. This is a personal report, not a confirmed drug reaction or an estimate of risk.

Read the adverse-experience report

Approval status

No thymosin beta-4 or TB-500 product is FDA approved for consumer recovery or performance uses. FDA has specifically described evidence gaps and potential risks for the thymosin beta-4 fragment used in compounding.

Ophthalmic Phase 3 studies completed

RGN-259, a thymosin beta-4 ophthalmic product candidate, has completed Phase 3 dry-eye studies. No thymosin beta-4 or TB-500 product is FDA approved.

Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.

Open questions

  • Whether effects in models translate into improved human recovery
  • How full-length thymosin beta-4 differs clinically from marketed fragments
  • Long-term safety and effects on abnormal blood-vessel or cell growth
  • Whether research products and products marketed online have the same identity and manufacturing quality

Summary

Clinical evidence does not establish broad recovery claims. Full-length thymosin beta-4, fragments and marketed products are not interchangeable.

Sources

Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.

  1. fdaFDA: bulk substances that may present significant safety risks

    FDA summaries of safety concerns and evidence gaps for selected bulk substances used in compounding.

  2. clinical trialsClinicalTrials.gov: RGN-259 ARISE-2 dry eye study

    Registry record for an ophthalmic thymosin beta-4-related study.

  3. clinical trialsClinicalTrials.gov: RGN-259 ARISE-3 dry eye study

    Registry record for an additional ophthalmic thymosin beta-4-related study.

  4. pubmedThymosin beta-4 and corneal inflammation review

    Peer-reviewed review discussing thymosin beta-4 in corneal wound healing and inflammation.

How we assess sources · Suggest a correction